Plasma Fractionation Market Outlook:
Plasma Fractionation Market size was over USD 36.95 Billion in 2025 and is poised to exceed USD 80.51 Billion by 2035, growing at over 8.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of plasma fractionation is estimated at USD 39.64 Billion.
The growth of the market is primarily attributed to the rising prevalence of bleeding disorders that occur when there is an issue that opposes the body’s blood clotting procedure. Based on the U. S. Centers for Disease Control estimates, there are nearly 3 million people nationwide, who have been suffering from bleeding disorders.
Immunoglobulins are derived from the fractionation of plasma and are very effective in treating various neurologic, immunologic, and hematologic diseases. Hence, the increasing prevalence of immunological diseases among the population is anticipated to increase the need for immunoglobulins & alpha-1-antitrypsin in numerous areas of medicine. In addition to that, the increased focus on characterizing and diagnosing immunodeficiency is also expected to generate a high demand for plasma fractionation in the next few years owing to the high number of diagnosed patients. Further, another major factor expected to contribute to the growth of the market is the surge in plasma collection centers across the globe. For instance, a pioneer in the creation of plasma-derived medicines, Grifols has opened its 300th plasma donation site in the United States, the second in New England and the first in the state of Massachusetts.
